Lawrence D. Kaplan, MD

Articles

Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

May 27th 2020

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Dr. Kaplan on the Use of PI3K Inhibitors in Follicular Lymphoma

February 8th 2020

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.

Dr. Kaplan on Frontline Treatment Options in Follicular Lymphoma

January 18th 2020

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Dr. Kaplan on a Study With Combination Immune Macrophage Checkpoint Blockade in Lymphoma

March 6th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin Lymphoma

January 29th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

Dr. Kaplan on the RELEVANCE Trial in Follicular Lymphoma

October 9th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCL

October 2nd 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Dr. Kaplan Discusses Combinations With Rituximab for MCL

February 7th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses combinations with rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Kaplan Discusses Rituximab Maintenance in MCL

January 11th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses remaining questions with rituximab (Rituxan) maintenance for patients with mantle cell lymphoma (MCL).